Janux Therapeutics (NASDAQ:JANX) Price Target Raised to $100.00

Janux Therapeutics (NASDAQ:JANX) had its price objective raised by research analysts at BTIG Research from $82.00 to $100.00 in a research note issued on Tuesday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 49.19% from the company’s previous close.

JANX has been the topic of several other research reports. Scotiabank decreased their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. UBS Group began coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Thursday, November 14th. Wedbush reissued an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $72.20.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $67.03 on Tuesday. The company’s fifty day simple moving average is $49.81 and its two-hundred day simple moving average is $45.77. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -34.34 and a beta of 3.30. Janux Therapeutics has a 1 year low of $7.79 and a 1 year high of $67.03.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year. Equities research analysts anticipate that Janux Therapeutics will post -1.35 EPS for the current year.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 50,000 shares of the stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the sale, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the sale, the chief executive officer now owns 257,054 shares in the company, valued at approximately $13,263,986.40. This trade represents a 8.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 445,610 shares of company stock valued at $20,578,666 in the last ninety days. 29.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Summit Securities Group LLC bought a new position in Janux Therapeutics in the 2nd quarter valued at $29,000. Amalgamated Bank raised its position in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the last quarter. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Janux Therapeutics in the second quarter valued at $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.